ArticleFrontiers in medicine2026
Prescribing and dosing patterns of ferric carboxymaltose for iron deficiency anemia: a real-world study from Saudi Arabia.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ferric carboxymaltose (FCM) is increasingly used for iron deficiency anemia, yet real-world prescribing patterns and dosing appropriateness remain poorly characterized, particularly in regions with high anemia prevalence. This study evaluated FCM prescribing patterns, dosing appropriateness, and associated clinical and financial implications at a Saudi tertiary hospital. Methods: This retrospective observational study examined adult patients who received FCM at a tertiary care general hospital in Saudi Arabia over a 6-month period. Dosing appropriateness was determined by comparing prescribed cumulative doses (PCD) with calculated cumulative doses (CCD) per the Summary of Product Characteristics. Hemoglobin response and financial impact were also assessed. Results: Of 182 patients treated with FCM, 79 met the inclusion criteria (97.5% female; mean age 34.6 ± 8.3 years). Overall, 82% of prescriptions exhibited an inappropriate cumulative dose, with 88% subtherapeutic. Mean PCD (1,118 ± 492 mg) was substantially lower than CCD (1,640 ± 438 mg), a mean under-dosing gap of 522.6 mg ( Discussion: Widespread subtherapeutic FCM dosing compromises therapeutic outcomes and increases downstream costs. Implementation of electronic clinical decision support and standardized dosing protocols is urgently needed to optimize intravenous iron utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.